New drug BW-50218 put to first safety test in healthy chinese volunteers
NCT ID NCT07577479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial is testing a single dose of an experimental drug called BW-50218 in 24 healthy Chinese adults. The main goal is to check for side effects and see how the drug moves through the body. Because it involves healthy participants, this study is not meant to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BW-50218
- What could go wrong
- This is an early-phase safety study in healthy people, so it cannot show whether BW-50218 works for any disease. The main risk is unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Argo Investigative Site
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injectable drug safely tackle weight? an early trial seeks answers
- Experimental biologic CND319 takes first steps toward taming autoimmune diseases
- Scientists map brain changes during Hour-Long DMT experience
- First human trial launches for experimental drug BY002
- New COPD drug candidate AN01 begins first human safety tests
- New drug PRX019 takes first step: safety check in healthy people